Immunic to Participate in Scientific and Investor Conferences in October
Immunic, Inc.(Nasdaq: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: — October 4-7: UEGW 2025 – United European Gastroenterology Week. Immunic's R&D team will attend this conference in Berlin, Germany. Data on […]